ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2679

Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension

Alexander Hannan1, Raed Dweik2, Kristin B. Highland3, Gustavo Heresi4, Adriano Tonelli5, William Messner6 and Soumya Chatterjee1, 1Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 2Respiratory Institute, Cleveland Clinic, Cleveland, OH, 3Rheumatology.org, Cleveland Clinic, Cleveland, OH, 4Respiratory Institute - Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, 5Pulmonary Medicine - Respiratory Institute, Cleveland Clinic, Cleveland, OH, 6Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Pulmonary complications and scleroderma, Pulmonary Involvement

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Survival in scleroderma associated pulmonary arterial hypertension (SSc-PAH) is known to be significantly worse compared to that in idiopathic pulmonary arterial hypertension (iPAH). However, specific factors contributing to the worse survival in SSc-PAH is currently unknown. Our objective was to investigate how the age at diagnosis of PAH and systolic blood pressure may influence mortality in these patients.

Methods: A retrospective chart-review was conducted comparing demographic, clinical and hemodynamic data from a total of 862 patients (686 with iPAH and 176 with SSc-PAH) enrolled in the Cleveland Clinic Pulmonary Hypertension Database. The diagnosis of PAH was confirmed by RHC, and the diagnosis of SSc was confirmed by a rheumatologist. We focused on the characteristics of age, systolic blood pressure (SBP) and cardiac output/cardiac index (on right heart catheterization) with regards to their effect on mortality in both the SSc-PAH and the iPAH groups.

Results: Among younger patients (age < 63) those with SSc-PAH had significantly worse survival compared to those with iPAH. Interestingly, a similar difference in mortality between the 2 groups was not seen in patients of age ≥ 63 years.

PAH Status Group

Age

P-value*

N

Est. Median Time-to-Death (years)

95% CI

Idiopathic PAH

Any non-missing

0.0002

598

10.26

(8.45, 12.00)

Scleroderma Associated

Any non-missing

159

5.33

(4.22, 7.59)

Idiopathic PAH

< 63

0.0087

439

14.41

(10.81, 16.49)

Scleroderma Associated

< 63

76

6.74

(4.22, 20.72)

Idiopathic PAH

≥ 63

0.9752

159

5.11

(4.58, 6.62)

Scleroderma Associated

≥ 63

83

4.75

(3.78, 7.59)

Scleroderma Associated

< 63

0.1061

76

6.74

(4.22, 20.72)

Scleroderma Associated

≥ 63

83

4.75

(3.78, 7.59)

Idiopathic PAH

< 63

<0.0001

439

14.41

(10.81, 16.49)

Idiopathic PAH

≥ 63

159

5.11

(4.58, 6.62)

A statistically significant difference in survival was also noted when comparing SSc-PAH patients with SBP >125 mmHg with those with SBP < 125 mmHg; the group with lower SBP had worse survival. A similar mortality difference was not noted in the iPAH patients.

PAH Status Group

Systolic Blood Pressure

P-value*

N

Est. Median Time-to-Death (years)

95% CI

Idiopathic PAH

Any non-missing

0.0007

559

10.02

(8.24, 11.84)

Scleroderma Associated

Any non-missing

151

5.33

(4.24, 7.68)

Idiopathic PAH

< 125

< 0.0001

277

9.48

(6.98, 12.31)

Scleroderma Associated

< 125

63

4.01

(2.51, 6.03)

Idiopathic PAH

≥ 125

0.2313

282

10.26

(8.23, 12.75)

Scleroderma Associated

≥ 125

88

7.68

(4.70, 18.60)

Scleroderma Associated

< 125

0.0099

63

4.01

(2.51, 6.03)

Scleroderma Associated

≥ 125

88

7.68

(4.70, 18.59)

Idiopathic PAH

< 125

0.8082

277

9.48

(6.98, 12.31)

Idiopathic PAH

≥ 125

282

10.26

(8.23, 12.75)

To determine if SBP served as a surrogate for cardiac output, we assessed Kendall tau-b correlations of SBP versus cardiac output and cardiac index (CI) (both by thermodilution and by the Fick equation); no strong correlation was noted. However, a correlation between CI < 2.5 L/min/m2 and mortality was noted. A similar mortality difference was not noted in the iPAH patients.

PAH Status Group

Cardiac Index (FICK) [L/min/m2]

P-value*

N

Est. Median Time-to-Death (years)

95% CI

Idiopathic PAH

Any non-missing

0.0126

470

9.38

(7.72, 11.50)

Scleroderma Associated

Any non-missing

142

5.59

(4.24, 8.19)

Idiopathic PAH

< 2.5

0.0003

261

9.38

(7.51, 14.41)

Scleroderma Associated

< 2.5

73

4.10

(3.38, 6.03)

Idiopathic PAH

≥ 2.5

0.9208

209

9.02

(6.81, 11.84)

Scleroderma Associated

≥ 2.5

69

10.74

(5.37, 18.59)

Scleroderma Associated

< 2.5

0.0192

73

4.10

(3.38, 6.03)

Scleroderma Associated

≥ 2.5

69

10.74

(5.37, 18.59)

Idiopathic PAH

< 2.5

0.5030

261

9.38

(7.51, 14.41)

Idiopathic PAH

≥ 2.5

209

9.02

(6.81, 11.84)

Conclusion: Younger age, lower SBP, and lower CI influences survival in SSc-PAH patients, but not in iPAH patients. Younger SSc-PAH patients have markedly lower survival times than similarly aged iPAH patients for unclear reasons. The relationship between lower SBP, decreased CI, and increased mortality has been previously noted in some smaller studies. These data may have important implications for treatment of SSc-PAH especially since some PAH therapies may decrease SBP.


Disclosure: A. Hannan, None; R. Dweik, None; K. B. Highland, None; G. Heresi, None; A. Tonelli, None; W. Messner, None; S. Chatterjee, None.

To cite this abstract in AMA style:

Hannan A, Dweik R, Highland KB, Heresi G, Tonelli A, Messner W, Chatterjee S. Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/mortality-is-increased-in-scleroderma-associated-pulmonary-arterial-hypertension-patients-with-younger-age-lower-systolic-blood-pressure-and-lower-cardiac-index-but-not-in-idiopathic-pulmonary-arte/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2017

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-is-increased-in-scleroderma-associated-pulmonary-arterial-hypertension-patients-with-younger-age-lower-systolic-blood-pressure-and-lower-cardiac-index-but-not-in-idiopathic-pulmonary-arte/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology